Cervical cancer prevention has changed significantly in recent years with less frequent screening and the addition of HPV testing as a stand-alone test along with the option for the Pap and HPV test together as cotesting. This session will review the appropriate use of Pap testing, the rationale for HPV testing along with the Pap (co-testing) in women 30 and older and the use of HPV testing as a primary screen (stand-alone test) in women 25 and older by two of the FDA approved HPV tests. There will be a discussion of the new American Cancer Society Guidelines for screening and a review of the new 2019 ASCCP Risk-Based Management Consensus Guidelines for management of abnormal screening and subsequent follow-up with case studies. These guidelines are a shift from results-based to risk-based management relative to the risk of an existing CIN 3 (pre-cancer). | 1.0 credits (0 pharmacology) | $27.50

This session will provide information regarding the identification of women and men at risk for fracture based on bone densitometry and their 10-year fracture risk using the FRAX calculation. Pharmacologic therapies will be reviewed including patient selection for first-line therapies and therapies for patients at extremely high risk and drug risks and benefits. Current controversies will be discussed including long-term use of bisphosphonates, adverse events including osteonecrosis of the jaw (ONJ) and atypical subtrochanteric femur fractures, and drug holidays. New concerns about the discontinuation of rank ligand inhibitors and the rapid increase in vertebral fractures will be discussed. Treatment of patients at high risk due to therapy such as aromatase inhibitors and androgen deprivation therapy will be presented. Case studies will be used to provide real clinical scenarios. | 1.0 credits (0.66 pharmacology) | $30

The Covid Pandemic brought with it a resurgence of discussion on vaccines and immunology. This session will review the basic function of the immune system. | 1.0 credits (0.66 pharmacology) | $30.00

As science evolves, cancer screening recommendations change, and keeping up with these changes is often difficult. This session will focus on the latest guidelines in cancer screening in primary care including cervical, prostate, colorectal, lung, anal, and oral-pharyngeal cancers. | 1.0 credits (0.33 pharmacology) | $35

This session will provide an update on legislative health policy changes in the last year that have implications for NP practice. It will also provide an overview of policy implications in the 2020-2030 Future of Nursing Report. Finally, it will provide action steps for NP’s to take to increase the policy advocacy. | 1.0 credits (0 pharmacology) | $27.50

Presentation of Case Studies in Neurology that may be seen in the primary care setting. The case studies will discuss determining the appropriate neurological assessment and evaluation of findings. Each case study will progress through confirming the diagnosis and planning for the patient. These case studies will include seizure disorder, restless leg syndrome, Parkinson disease, muscle spasms. | 1.0 credits (0.33 pharmacology) | $30

This session will provide an overview of the current state of diversity, equity, and inclusion (DEI) in the nursing / NP profession by drawing on historical and contemporary DEI data trends. It will also provide an overview of the recently released ANA Commission on Racism in Nursing Report. Finally, it will discuss several things that NP’s can do to intentionally improve DEI matters in the nursing/NP profession. | 1.0 credits (0 pharmacology) | $27.50